Sugi Predict

Sugi Predict / Compounds / SCHEMBL14949219

SCHEMBL14949219

SCHEMBL14949219

Cc1cccc(Nc2nnc(-c3ccc(Oc4ccnc5cc(Cl)ccc45)cc3)[nH]2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 11/20 0.44
▸ PDGFRA P16234 5/20 0.44
▸ FGFR2 P21802 4/20 0.40
▸ APP P05067 3/20 0.40
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ LCK P06239 2/20 0.37
▸ MET P08581 2/20 0.37
▸ TEK Q02763 2/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CB P42338 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ AURKA O14965 1/20 0.37
▸ CSF1R P07333 1/20 0.37
▸ BRAF P15056 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ NR4A2 P43354 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949208 0.93 KDR (0.46) KDRPDGFRAFGFR2LCKMET
SCHEMBL14949343 0.92 KDR (0.40) KDRPDGFRAFGFR2APPLMNA
SCHEMBL14949214 0.90 KDR (0.49) KDRPDGFRAFGFR2LCKMET
SCHEMBL14949232 0.89 KDR (0.46) KDRPDGFRAFGFR2METBRAF
SCHEMBL14949644 0.89 KDR (0.44) KDRPDGFRAFGFR2SMN1; SMN2LCK
SCHEMBL14949218 0.87 KDR (0.46) KDRPDGFRAFGFR2LCKMET
SCHEMBL12336224 0.87 BRAF (0.48) KDRPDGFRABRAF
SCHEMBL16786015 0.86 KDR (0.60) KDRPDGFRAFGFR2LCKMET
SCHEMBL14949224 0.85 FGFR2 (0.41) KDRPDGFRAFGFR2METTEK
SCHEMBL14949223 0.85 KDR (0.49) KDRPDGFRAFGFR2LCKMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 — — US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 — — US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 — — US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 — — US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 KDR 533/4885PDGFRA 498/4885FGFR2 851/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDR 533/4885PDGFRA 498/4885FGFR2 851/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 KDR 533/4885PDGFRA 498/4885FGFR2 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.